Morphic Holding (MORF) Stock Price
Morphic Holding Price
Revenue at Morphic Holding has contracted by 31.1% per year over the past 5 years to 521,000.00 USD. For Morphic Holding, the net margin of -29,192.9% is down versus -255.2% a few years ago. The consensus 12-month price target for Morphic Holding is 58.14 USD, about 2.0% above where the stock trades today. Of 15 analysts, 7 rate the stock a buy — an overall Hold consensus.
Morphic Holding stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Morphic Holding over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Morphic Holding stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Morphic Holding's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Morphic Holding Price |
|---|
Morphic Holding Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Morphic Holding Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 3.00 | 16.00 | 44.00 | 19.00 | 70.00 | – | 2.00 | 2.00 | – | 1.00 | 156.00 | 381.00 |
| – | – | 433.33 | 175.00 | -56.82 | 268.42 | – | – | – | – | – | 15,500.00 | 144.23 |
| – | 100.00 | -225.00 | 100.00 | 100.00 | 100.00 | – | 100.00 | 100.00 | – | 100.00 | 100.00 | 100.00 |
| -14.00 | 3.00 | -36.00 | 44.00 | 19.00 | 70.00 | 70.00 | 2.00 | 2.00 | 70.00 | 1.00 | 156.00 | 381.00 |
| -16.00 | -24.00 | -46.00 | -47.00 | -95.00 | -63.00 | -178.00 | -228.00 | -248.00 | -272.00 | -312.00 | -226.00 | -128.00 |
| – | -800.00 | -287.50 | -106.82 | -500.00 | -90.00 | – | -11,400.00 | -12,400.00 | – | -31,200.00 | -144.87 | -33.60 |
| -16.00 | -23.00 | -43.00 | -44.00 | -94.00 | -59.00 | -152.00 | -192.00 | -184.00 | -226.00 | -254.00 | -175.00 | -58.00 |
| – | 43.75 | 86.96 | 2.33 | 113.64 | -37.23 | 157.63 | 26.32 | -4.17 | 22.83 | 12.39 | -31.10 | -66.86 |
| 42.00 | 1.00 | 16.00 | 31.00 | 36.00 | 38.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Morphic Holding generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Morphic Holding retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Morphic Holding's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Morphic Holding has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Morphic Holding's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Morphic Holding stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Morphic Holding Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Morphic Holding business model & stock analysis
Morphic Holding SWOT Analysis
Strengths
Morphic Holding Inc possesses several strengths that contribute to its success in the market. One of its key strengths is its strong and experienced management team, which has a deep understanding of the industry. This enables the company to make informed decisions and navigate challenges effectively.
Furthermore, Morphic Holding Inc has a diverse portfolio of innovative products and solutions, which gives it a competitive edge in the market. Its focus on research and development ensures that it stays ahead of its competitors by continuously improving and expanding its offerings.
Weaknesses
While Morphic Holding Inc has numerous strengths, it also faces certain weaknesses that need to be addressed. One of its weaknesses is its limited market presence compared to some of its larger competitors. This makes it more challenging for the company to penetrate new markets and gain significant market share.
Additionally, Morphic Holding Inc heavily relies on a few key customers for a significant portion of its revenue. This dependency poses a risk, as any loss of these customers could have a negative impact on the company's financial performance.
Opportunities
There are several opportunities available for Morphic Holding Inc to capitalize on and fuel its growth. The increasing demand for its products and solutions, driven by market trends and technological advancements, presents a significant opportunity for the company to expand its customer base and increase its market share.
Furthermore, the company has the potential to enter new geographic markets where its products are not yet widely available. By strategically targeting these untapped markets, Morphic Holding Inc can tap into new revenue streams and diversify its customer base.
Threats
Despite its strengths and opportunities, Morphic Holding Inc also faces certain threats that could impact its performance. One of the major threats is intense competition from established players in the industry. This competition can lead to pricing pressures and reduced market share if the company is unable to differentiate itself effectively.
Moreover, regulatory changes and compliance requirements pose a potential threat to Morphic Holding Inc. Changes in regulations or non-compliance with existing ones can create operational challenges and legal liabilities, affecting the company's reputation and financial stability.
Morphic Holding Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Morphic Holding Segments
Morphic Holding Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Morphic Holding historical P/E ratio, EBIT multiple, and P/S ratio
Morphic Holding annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Morphic Holding shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Morphic Holding forecasts and price targets in August 2026
Analyst Price Targets 2026Morphic Holding Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/26/2024 | Maintained | Sector Perform | 52 | |
| 7/22/2024 | Maintained | Hold | – | |
| 7/9/2024 | Downgrade | BuyHold | 60 | |
| 7/9/2024 | Downgrade | OutperformSector Perform | 52 | |
| 7/9/2024 | Downgrade | OutperformMarket Perform | – | |
| 3/8/2024 | Maintained | Buy | 59 | |
| 9/28/2023 | Maintained | Outperform | – | |
| 9/27/2023 | Maintained | Outperform | – | |
| 9/25/2023 | Maintained | Hold | – | |
| 9/25/2023 | Downgrade | BuyNeutral | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Morphic Holding Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 4/23/2024 | -0.97USD | - | 0.00USD | - | 2024 Q1 |
| 2/21/2024 | -0.87USD | - | 0.00USD | - | 2023 Q4 |
| 8/1/2023 | -0.85USD | - | 2.64 MUSD | - | 2023 Q2 |
| 5/2/2023 | -0.86USD | - | 2.47 MUSD | - | 2023 Q1 |
| 2/22/2023 | -0.89USD | - | 2.74 MUSD | - | 2022 Q4 |
| 11/2/2022 | -0.85USD | - | 3.28 MUSD | - | 2022 Q3 |
| 8/3/2022 | -0.87USD | - | 3.13 MUSD | - | 2022 Q2 |
| 5/4/2022 | -0.83USD | - | 3.16 MUSD | - | 2022 Q1 |
| 2/24/2022 | -0.50USD | - | 12.57 MUSD | - | 2021 Q4 |
| 11/4/2021 | -0.77USD | - | 5.27 MUSD | - | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Morphic Holding stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Morphic Holding shareholder structure
| % | Name |
|---|---|
0.00945% | |
0.00000% | |
0.00000% | |
0.00000% | |
0.00000% | |
0.00000% |
Morphic Holding Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
15.80% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
9.70% | SEC ↗ | |
9.35% | SEC ↗ | |
7.60% | SEC ↗ | |
7.60% | SEC ↗ | |
7.60% | SEC ↗ | |
7.60% | SEC ↗ |
Morphic Holding Executives and Management Board
5 members · 20 % women
Management
Mr. Michael Thompson
President, Treasurer, Director · since 2024
Ms. Katie Lodato
Assistant Treasurer
Mr. Jonathan Groff
Assistant Secretary
Board of Directors
Mr. Christopher Anderson
Company Secretary, Director · since 2024
Mr. Gordon Brooks
Director
Morphic Holding Supply Chain
Morphic Holding Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.59 | -0.42 | 0.55 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.79 | 0.87 | -0.47 | ||
| 2 | 0.71 | 0.86 | 0.03 | ||
| 3 | -0.67 | -0.85 | 0.22 |
Frequently asked questions about Morphic Holding
The business model of Morphic Holding Inc is focused on discovering and developing oral small molecule integrin therapeutics. These therapeutics aim to treat chronic diseases by selectively targeting integrins, which are proteins involved in cell adhesion and signaling. Morphic Holding Inc's proprietary Morphic Integrin Therapeutics (MIT) platform enables the design of integrin-targeting drug candidates with improved selectivity, efficacy, and safety profiles. By leveraging their expertise in drug discovery and integrin biology, Morphic Holding Inc strives to advance potential treatments for conditions such as autoimmune diseases, fibrosis, and cancers.
Morphic Holding Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Morphic Holding Inc in the market include pharmaceutical companies such as Biogen Inc, Amgen Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the biotechnology industry and focus on developing innovative therapies and drugs for various conditions. By being aware of the competitive landscape, investors and individuals interested in Morphic Holding Inc can gain insights into the market dynamics and potential challenges the company may face.
Morphic Holding Inc is a reputable company specializing in the field of biotechnology. Founded in 2014, Morphic focuses on developing integrin-targeted therapeutics for chronic inflammatory and autoimmune diseases. The company boasts a talented team of scientists and researchers dedicated to advancing new treatment options. Morphic has collaborated with several renowned institutions and pharmaceutical companies to develop novel drugs targeting specific integrins, thus making significant strides in the field of biopharmaceuticals. With their rich history and strong track record, Morphic Holding Inc continues to make promising advancements in the biotechnology industry, showcasing their commitment to improving global healthcare.
Morphic Holding Inc has achieved significant milestones since its establishment. The company successfully completed its initial public offering (IPO) and listed on the Nasdaq stock exchange under the ticker symbol MORF. Moreover, Morphic Holding Inc has made notable advancements in its drug discovery research and development programs, particularly in the field of integrin-targeted therapies. This has allowed the company to progress multiple drug candidates into various stages of clinical trials, highlighting its dedication to addressing unmet medical needs. Morphic Holding Inc continues to strive for excellence in the pharmaceutical industry, constantly pushing boundaries to bring innovative treatments to patients worldwide.
Morphic Holding Inc is primarily present in the United States.
Morphic Holding Inc represents a set of core values and corporate philosophies that drive their operations. With a focus on innovation, they are committed to pushing boundaries and delivering groundbreaking solutions in the biopharmaceutical industry. As a company, Morphic Holding Inc values integrity, transparency, and ethical practices, ensuring they uphold the highest standards in all their endeavors. By fostering a collaborative environment, they encourage teamwork, diverse perspectives, and a shared passion for making a positive impact on patients' lives. Morphic Holding Inc's dedication to excellence and patient-centric approach defines their identity and drives their pursuit of pioneering therapeutic advancements.
Analysts currently set an average price target of 59.60 USD for the Morphic Holding stock (median: 58.14 USD), implying +4.6 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Morphic Holding stock: 7 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Morphic Holding to generate revenue of 408,000.00 USD and earnings per share of -5.40 USD.
Converted at the current exchange rate, the Morphic Holding share trades at 49.27 EUR (56.99 USD).
The Morphic Holding share (MORF) is listed on 4 stock exchanges, including: NASDAQ (MORF), Frankfurt (31Y.F), München (31Y.MU), Düsseldorf (31Y.DU).
Morphic Holding Inc is a US-based biotechnology company focused on the discovery and development of drugs based on the science of integrin pharmacology. The company was founded in 2015 and is listed on the Nasdaq stock exchange under the symbol "MORF". This article will describe the business model of Morphic Holding Inc. Integrin pharmacology is a novel therapeutic strategy that specifically targets integrins to modulate specific cell/tissue interactions. Integrins are protein molecules on the surface of cells that are responsible for cell adhesion, cell migration, and signal transduction, making them important targets for drug development. Morphic Holding Inc has a strong portfolio of proprietary molecules that modulate integrins to treat diseases such as inflammatory bowel disease, fibrosis, cancer, pain, and autoimmune diseases. The company also has strategic partnerships with leading pharmaceutical companies such as AbbVie, Janssen, and Schrödinger to further intensify their research. Morphic's business model involves developing innovative drugs based on integrin pharmacology and licensing them to pharmaceutical companies. The company pursues a dual strategy by independently advancing its own pipeline while also demonstrating the value of its technology platform through collaborations. Morphic's product portfolio includes several drugs in development targeting fibrosis, inflammatory bowel disease, cancer, and autoimmune diseases. The lead product candidate, MORF-057, is a selective integrin α4β7 antagonist developed for the treatment of inflammatory bowel disease and is currently in Phase 2 clinical trials. Furthermore, the company recently completed the acquisition of Morphic Therapeutic Europe Limited, a company focused on researching and developing integrin-mediated tumor metastasis blockade. This acquisition expands Morphic's portfolio with innovative preclinical drug candidates for the treatment of cancer based on integrins. In summary, Morphic Holding Inc has an innovative business model based on integrin pharmacology. The company develops drugs targeting a variety of diseases by specifically modulating integrins. Their products are currently in development and have the potential to achieve significant therapeutic advancements. Through strategic partnerships and acquisitions, the company is further expanding its position in the biotechnology sector.
The expected revenue of Morphic Holding is 408,000.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Morphic Holding is -226.92 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Morphic Holding is currently -10.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Morphic Holding stock.
The price-to-sales ratio (P/S) of Morphic Holding is currently 5,866.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Morphic Holding stock.
The Eulerpool Quality Score for Morphic Holding is 2/10.
The ISIN of Morphic Holding is US61775R1059. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Morphic Holding is A2PLX9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Morphic Holding is MORF. The ticker symbol is used to trade Morphic Holding shares on the stock exchange.
Morphic Holding paid dividends every year for the past 0 years.
Morphic Holding is assigned to the 'Health' sector.
The dividends of Morphic Holding are distributed in USD.
Morphic Holding stock
Morphic Holding Peer Group
Morphic Holding Ticker
Morphic Holding FIGI
All fundamentals and in-depth analysis of Morphic Holding
Our stock analysis for Morphic Holding stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Morphic Holding. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.